指南与共识放疗物理与技术

美国国家综合癌症网络(NCCN)临床指南中放射治疗推荐的证据等级

Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines.
指南 / 共识 · Adv Radiat Oncol · 2021-10-29

该研究系统评估了NCCN临床指南中美国最常见的20种癌症的放射治疗推荐所依据的共识与证据(CE)类别分布,并与全身治疗推荐进行比较。结果显示,所有放射治疗推荐中I类CE仅占9.7%,IIA类占80.6%;全身治疗推荐的I类CE比例显著高于放射治疗推荐(12.3% vs 9.7%,P = .043)。

要点

  • NCCN放射治疗推荐中I类CE仅占9.7%,IIA类占80.6%。
  • 宫颈癌和乳腺癌的I类CE比例最高,分别为33%和31%。
  • 全身治疗推荐的I类CE比例显著高于放射治疗推荐(12.3% vs 9.7%,P = .043)。

核心结论

  • NCCN指南中仅9.7%的放射治疗推荐为I类CE,乳腺和宫颈癌的放射治疗证据等级最高。
  • 尽管该领域取得重大进展,多数NCCN放射治疗推荐仍基于一致的专家意见而非更高等级证据。

研究设计与样本

  • 系统评估美国最常见的20种癌症在NCCN临床指南中至少10条放射治疗推荐的CE类别分布。
  • 采用χ2检验比较放射治疗与全身治疗指南的证据分布,采用两比例两尾z检验比较I类CE比例,P < .05为显著。

主要发现

  • 全部放射治疗推荐中I类、IIA类、IIB类和III类CE的比例分别为9.7%、80.6%、8.4%和1.3%。
  • 宫颈癌和乳腺癌的I类CE比例最高,分别为33%和31%。
  • 肝胆癌、骨癌、胰腺癌、黑色素瘤和子宫癌无放射治疗I类CE推荐。
  • 全身治疗推荐与放射治疗推荐的CE分布存在显著差异(χ2统计量64.16,P < .001)。
  • 全身治疗推荐的I类CE比例显著高于放射治疗推荐(12.3% vs 9.7%,P = .043)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The National Comprehensive Cancer Network (NCCN) clinical guidelines influence medical practice, payor coverage, and standards of care. The levels of evidence underlying radiation therapy recommendations in NCCN have not been systematically explored. Herein, we aim to systematically investigate the NCCN recommendations pertaining to the categories of consensus and evidence (CE) for radiation therapy. METHODS AND MATERIALS: We evaluated the distribution of CE underlying current treatment recommendations for the 20 most prevalent cancers in the United States with at least 10 radiation therapy recommendations in the NCCN clinical guidelines. For context, the distribution of evidence in the radiation therapy guidelines was compared with that of systemic therapy using a χ2 test. The proportion of category I CE between radiation and systemic therapy was compared using a 2-proportion, 2-tailed z-test in total and for each disease site. A P value of < .05 was considered significant. RESULTS: Among all radiation therapy recommendations, the proportions of category I, IIA, IIB, and III CE were 9.7%, 80.6%, 8.4%, and 1.3%, respectively. When analyzed by disease site, cervix and breast cancer had the highest portion of category I CE (33% and 31%, respectively). There was no radiation therapy category I CE for hepatobiliary, bone, pancreatic, melanoma, and uterine cancers. There was a significant difference in the distribution of CE between the systemic therapy recommendations and the radiation therapy recommendations (χ2 statistic 64.16, P < .001). Overall, there was a significantly higher proportion of category I CE in the systemic therapy recommendations compared with the radiation therapy recommendations (12.3% vs 9.7%, P = .043). CONCLUSIONS: Only 9.7% of radiation therapy recommendations in NCCN guidelines are category I CE. The highest levels of evidence for radiation therapy are in breast and cervical cancers. Despite major advances in the field, these data underline that the majority of NCCN radiation therapy recommendations are based on uniform expert opinion and not on higher level evidence.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Noy MA, Rich BJ, Llorente R, et al. Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines. Adv Radiat Oncol. 2021. PMID: 34869943. doi:10.1016/j.adro.2021.100832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。